The sharp reversal in profitability was partly driven by a 12.5% year-on-year decline in revenue, which fell to ₹384 crore from ₹439 crore a year ago.
“While this has been a challenging year for Indoco, there are several optimistic triggers which give us confidence for a better future, both in the short as well as long term,” said Aditi Panandikar, Managing Director.
The board of directors has recommended a final dividend of ₹0.20 per equity share (face value ₹2), subject to shareholder approval at the upcoming Annual General Meeting.
Also Read: Q4 Results Live Updates: Strides Pharma beats FY25 guidance; ITC shares fall 2% ahead of earnings
Following the earnings announcement, shares of Indoco Remedies saw sharp fall. The stock fell over 12% from its day’s high of ₹273.75 to hit a low of ₹240.25.
As of 3:13 PM, the stock was trading at ₹242.40 on the BSE, down 7% for the day.
First Published: May 22, 2025 3:22 PM IST
